Guidant loses in drug-coated stent decision
This article was originally published in Clinica
Executive Summary
Guidant's attempt to get a drug-coated stent on the market has suffered a severe setback after a US district court judge ruled that the company's agreement with Cook - giving it access to the drug paclitaxel - was a "sham". The deal between the two companies violated an earlier co-exclusive agreement between Boston Scientific, Cook and Angiotech Pharmaceuticals for Angiotech's proprietary drug paclitaxel, the judge said in the ruling in favour of Boston Scientific.